Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | SMO | Q99835 | 2/20 | 0.35 |
| ▸ | IDE | P14735 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660643 | 0.89 | DPP4 (0.38) | ALDH1A1HPGDIDE | |
| SCHEMBL13660483 | 0.85 | DPP4 (0.37) | ALDH1A1HPGDIDE | |
| SCHEMBL13660486 | 0.66 | NAMPT (0.42) | HPGD | |
| SCHEMBL21740219 | 0.65 | KMT2A (0.38) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL13660641 | 0.65 | ALDH1A1 (0.51) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL18448582 | 0.63 | CLK1 (0.47) | CLK1MEN1KMT2AATMALDH1A1 | |
| SCHEMBL4271934 | 0.62 | HRH4 (0.53) | — | |
| SCHEMBL6180952 | 0.62 | KMT2A (0.53) | CLK1MEN1KMT2AATMALDH1A1 | |
| SCHEMBL13660480 | 0.62 | NOS3 (0.34) | — | |
| SCHEMBL21739722 | 0.61 | ALDH1A1 (0.37) | MEN1KMT2APOLBALDH1A1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064715-A1 | 6-Azaindole Compound | RELA, NFKBIA, GPR119 | CLK1 1405/4885MEN1 2705/4885KMT2A 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.